Cordis Launches Integrated Solutions for Transradial Care

PARIS, May 16, 2011 - Cordis announces the launch in Europe of Radial Solutions, a
complete portfolio for transradial interventions. New to the portfolio is the
Cordis RADIALSOURCE(TM) Transradial Access Kit. RADIALSOURCE(TM) Transradial
Sheaths are designed to provide physicians with atraumatic and smooth access
to the radial artery during diagnostic and interventional procedures and is a
result of Cordis' long standing commitment to driving innovation.

The rate of transradial procedures (TRA) in cardiovascular
interventions is growing. Several studies have shown lower complication rates
associated with transradial compared to the femoral approach.[1] Cordis, a
division of Johnson & Johnson Medical, is dedicated to providing complete
solutions for cardiovascular interventions. The "Radial Solutions" portfolio,
including the RADIALSOURCE(TM) Transradial Sheaths, diagnostic and guiding
catheters has been created in close cooperation with clinical partners to
meet the requirements for this technique.

TRA offers significant benefits for patients, especially in
patients who are at high risk of bleeding. Completing haemostasis after TRA
is simpler as the artery is superficial and easier to compress, increasing
patient comfort.

Cordis Radial Solutions portfolio comprises of Cordis' well
known guiding and diagnostic catheters with new specific radial shapes,
transradial sheath introducer, guidewires and professional education
training.

The RADIALSOURCE(TM) Transradial Sheath incorporates a new
tapering design in conjunction with a lubricious coating, offering the
benefits of low insertion force with a smooth atraumatic entry, while
enabling stability during procedure and ease of removal. Customers will be
offered a choice of kit with a bare metal spring mini guidewire or a
polymer-coated mini guidewire.

Cordis is dedicated to professional education and is committed
to expanding the use of radial approach to improve patient safety through
teaching and tutoring to improve outcomes. "We offer comprehensive training
through our Cordis Cardiac & Vascular Institute programme, conducted in
co-operation with leading interventional cardiologists, who
have the goal of sharing expertise for better patient outcomes," said
Christian Spaulding, M.D. Worldwide Vice President, Medical Affairs, Cordis
Corporation

About Cordis Corporation

For more than 50 years, Cordis Corporation, a Johnson &
Johnson company, has been a worldwide leader in the development and
manufacture of interventional vascular technology. Through the company's
innovation, research and development, Cordis partners with interventional
cardiologists worldwide to treat millions of patients who suffer from
vascular disease.

[1] RIVAL Trial - Published online (www.thelancet.com)
April 4, 2011 DOI:10.1016/S0140-6736(11)60404-2

Name: Hans Vanavermaete Director, Communications & Public Affairs (m) +32-478-447-278